Now I have all the information I need. Let me produce the final consolidated review.

## Summary

ProteinVista revives full-atom 3D CNNs for protein representation learning, using adaptive boxing (64³–160³ voxel grids), five-channel heavy-atom density encoding, and contrastive pre-training on ~500K AlphaFold2 structures aligned to ESM-2 embeddings. It demonstrates competitive or better results than ESM-2 on transporter-substrate prediction (TSP), enzyme-substrate prediction (ESP), and drug-target IC50 regression, while being substantially faster at inference (20s vs. 426s per 1K proteins on A100) and pre-training with ~1% of the GPU-hours.

## Strengths

1. **Well-motivated architectural choice.** The paper correctly identifies a genuine gap: residue-level graphs omit atom-level geometry critical for binding-site chemistry. Returning to full-atom 3D CNNs with adaptive boxing (Section 2.1) is a practical solution to the sparsity problem that historically kept 3D CNNs off whole-protein tasks.

2. **Honest negative results.** Section 3.4 reports that ProteinVista underperforms ESM-2 on GO term prediction (Fmax 0.57 vs. 0.62) with a clear explanation. Section 4.1 shows degradation on low-confidence AF2 structures and low-homology proteins. This willingness to report where the method does not work increases credibility.

3. **Informative ablations.** Section 4.2 disentangles contributions of multi-view inference, pre-training objective, and voxel resolution. The finding that fine-tuning without rotation augmentation has virtually no effect (-0.1% R²) while single-view inference degrades by 6.4% is non-obvious. The Rosetta-score pre-training ablation (1.0% worse than contrastive alignment) shows the model does not critically depend on ESM-2 bootstrapping.

4. **Genuine compute efficiency.** Pre-training: 48 hours on 4 A100s (~500K structures) vs. ~7 days on 128 H100s (250M sequences) for ESM-2. Fine-tuning: 20s vs. 426s per 1K proteins (A100). These comparisons are honestly presented and compelling.

## Weaknesses

### Fatal
None.

### Major

1. **The "outperforms sequence transformers" framing is undermined by the ESM-2-dependent pre-training objective and imprecise claims.** The pre-training (Section 2.3) uses contrastive alignment to ESM-2 embeddings via InfoNCE loss. The abstract presents ProteinVista as "pre-trained on over 500,000 AlphaFold-2 structures" without mentioning that the pre-training objective was alignment to ESM-2. The contributions list (Section 1) also omits this detail. Additionally, the abstract claims ProteinVista "outperforms sequence transformers on three benchmarks" — but on the ESP benchmark, ProteinVista alone achieves 91.8% Acc vs. ESM-2_650M's 91.9% (essentially tied), so this claim relies on the ESM-ProteinVista ensemble. The title phrase "Outperforms Sequence Transformers" is also overstated given the tied ESP result and the ESM-2-aligned pretraining. The ablation shows that a Rosetta-score-pretrained model (no ESM-2) is only 1.0% worse on IC50, which partially mitigates this concern — but without full downstream results (TSP, ESP, GO) for the Rosetta-only model, the paper cannot cleanly separate the contribution of structure from the contribution of ESM-2 bootstrapping.

2. **SOTA comparison lacks crucial experimental details and some metrics conflict with the claimed superiority.** On ESP (Table 1), ESM-ProteinVista_OP achieves higher Acc (94.4%) and MCC (0.86) than ProSmith-ESP (94.2%, 0.85) but a *lower* ROC-AUC (0.967 vs. 0.972). This tradeoff is not discussed. It is also unclear whether the SOTA baselines (SPOT, ProSmith-ESP, Fusion_ESP) use the same training/validation/test splits as ProteinVista. No statistical significance is reported for these SOTA comparisons (unlike the ESM-2 comparisons where p-values are given).

3. **Rotation "invariance" claims overstate what the augmentation scheme provides.** The augmentation (Section 2.4) applies only 90° rotations and mirror reflections about Cartesian axes — the symmetry group of a cube, not full SO(3). The introduction states "We aimed to achieve rotation-invariant predictions through extensive 3D augmentations" (line 31). While multi-view averaging at inference is a reasonable practical compromise, the gap between cubic-group invariance and SE(3) invariance is not discussed, and the phrase "rotation-invariant" is stronger than what the scheme guarantees.

### Minor

1. **No variance or confidence intervals reported for main results.** All metrics are point estimates without variance across runs. This makes it difficult to judge whether improvements that are modest in absolute terms (e.g., +0.2% Acc on ESP) are robust across random initializations. Confidence intervals or standard deviations from multiple fine-tuning runs would strengthen the analysis.

2. **Only five heavy atom types are encoded (C, N, O, S, P), omitting metal ions.** Metal ions (Zn²⁺, Fe²⁺/³⁺, Mg²⁺, Ca²⁺, Cu²⁺, etc.) are catalytically critical in an estimated ~30–40% of enzymes. The paper neither acknowledges this limitation nor analyzes whether affected test cases show degraded performance.

3. **No analysis of dataset overlap between pre-training set and test sets.** The paper does not check whether test proteins share homology with the ~500K AF2 pre-training structures. If test proteins are largely in-distribution for ProteinVista while ESM-2 was pre-trained on different data, the comparison could be confounded. The similarity analysis in Section 4.1 bins by similarity to the *training set* (fine-tuning), not the *pre-training set*.

4. **Optimized pipeline hyperparameters not reported.** The multi-stage pipeline (Section 3.3: MolFormer weight update → embedding extraction → contrastive network training → prediction averaging) involves several unreported design choices (contrastive network architecture, temperature, training hyperparameters).

### Trivial
None.

## Nice-to-Haves
- Report full TSP, ESP, and GO results for the Rosetta-score-pretrained model (no ESM-2 alignment) to cleanly separate structure from ESM-2 bootstrapping.
- Add confidence intervals or standard deviations for all main results.
- Clarify whether SPOT, ProSmith-ESP, and Fusion_ESP use identical data splits.
- Stratify results by presence of metal ions to test the 5-atom-type limitation.
- Explicitly state whether ESM-2 embeddings are frozen or fine-tuned during contrastive pre-training.

## Removed Points
These points are flagged to be removed — treat them with caution.

- **"Formula on line 57 appears garbled"** — This is a formatting artifact from PDF extraction; the original paper does not have this issue (per instructions).
- **"Missing related works"** — Cannot be confirmed; instructions prohibit mentioning missing related works.
- **"Does not discuss how proteins larger than 160³ are handled"** — Paper explicitly states "cropped at the bounding box" (line 59). While terse, this is a clear statement.
- **"Undisclosed hyperparameters"** — Minor implementation details; Table S1 (stripped by parser) likely contains them. Not a meaningful weakness.
- **"ESM-2 frozen or fine-tuned during pre-training"** — A clarification question, not a weakness. The text implies ESM-2 provides fixed embeddings.
- **"Compute-efficient in title should be qualified"** — A framing suggestion, not a weakness. The paper correctly reports FLOPs and wall-clock time, making the tradeoff transparent.
- **"Addressing an important problem"** — Generic strength; removed.
- **"Three stated contributions do not mention contrastive alignment"** — Partially true, but this is subsumed by Major Weakness #1.

## Novel Insights
The reviewer raises a useful observation that the harsh-critic review did not fully develop: the paper's strongest evidence for the value of structure *per se* is the Rosetta-score ablation showing only 1.0% R² degradation on IC50 without ESM-2 alignment. But this evidence is only shown for one task (IC50), not for TSP, ESP, and GO where the headline claims are made. The fact that the paper's central narrative (structure beats sequence) depends on a single ablation on a single task, while the main results all use the ESM-2-aligned model, is a structural weakness in the evidence chain that should be fixed by extending the Rosetta ablation to all benchmarks.

## Suggestions
1. Reframe the abstract and introduction to accurately describe the pre-training as contrastive alignment to ESM-2 embeddings, not simply "pre-trained on AlphaFold-2 structures." Consider softening "outperforms" to "is competitive with" where the data supports it (ESP).
2. Report full downstream results for the Rosetta-score-pretrained model to demonstrate that structure alone (without ESM-2 bootstrapping) drives the observed performance.
3. Clarify data splits used for SOTA baselines and discuss the ROC-AUC tradeoff on ESP.
4. Replace "rotation-invariant" with "rotation-robust" throughout and discuss the cubic-group limitation.
5. Add confidence intervals for all main results.
6. Acknowledge and analyze the 5-atom-type limitation, particularly for metal-containing proteins.
7. Add a homology analysis between the pre-training set (~500K AF2 structures) and test sets.

---

**Calibration Anchors (retrieved across rounds):**

| Path | Avg Score | Round | Comparison |
|------|-----------|-------|------------|
| iBAWiEjogY (ProteiNexus) | 3.67 | R1 | Weaker: less novel architecture, unclear data splits; ProteinVista stronger |
| jqx5XI4Yr3 (ProteinAdapter) | 3.40 | R1 | Weaker: adapter-based approach on existing LPMs; ProteinVista more novel |
| rEQ8OiBxbZ (LEGO 3D Mol) | 3.00 | R1 | Weaker: molecular (not protein) pretraining with equivariance concerns |
| QKywN4BbqA (E³former) | 5.25 | R1 | Comparable tier: both address protein structure representation; ProteinVista has better compute analysis and honest negatives, similar framing issues |
| tNAucRS0QQ (BIT) | 5.25 | R2 | Comparable: multi-modal protein-ligand model, rejected for methodological concerns; ProteinVista cleaner but has its own framing problems |
| AXbN2qMNiW (Prot-ligand binding) | 5.67 | R2 | Slightly stronger: accepted despite concerns; ProteinVista has framing issues that need revision |
| BEH4mGo7zP (ProteinINR) | 5.75 | R2 | Slightly stronger: accepted with marginal improvements; ProteinVista would benefit from similar level of experimental rigor |
| sTYuRVrdK3 (ProteinWorkshop) | 6.25 | R1 | Stronger: comprehensive benchmark, different contribution type |

**Round 1 bracket:** 4.5–6.0. **Narrowing:** Compared against the 5.25–5.75 range anchors, the paper's framing issues (ESM-2 alignment not disclosed in abstract/contributions, overstated "outperforms" claim, rotation claims) are more significant than the concerns in accepted papers like ProteinINR (5.75) or Prot-ligand binding (5.67). These issues push it to the lower end of this range.

MY FINAL SCORE: <score>5.0</score>
MY FINAL DECISION: <decision>Reject</decision>